Clinical trials: Lenvatinib, open to volunteers
Renal Cell Carcinoma
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
- Trial name
- NCT05733715
- Testing
- Pembrolizumab infusion, Lenvatinib tablet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
This is a prospective, open, multi-cohort phase II study The study included a screening period (participants signed informed consent no more than 28 days before the first treatment in the study), a treatment period (treatment…
- Trial name
- NCT07909265
- Testing
- Cadonilimab,Lenvatinib
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital